Search results for "Opioid use disorder"


 
Results 1 - 10 of about 52 for "Opioid use disorder".
Sort by: Relevance | Newest | Oldest

Telehealth visits may improve outcomes for opioid use disorder

A cross-sectional study of U.S. insurance claims found that buprenorphine initiation during a telehealth visit was associated with a 36% lower overdose rate than in person and that patients in the former group were more likely to refill their prescriptions.
https://acpinternist.org/weekly/archives/2023/09/12/1.htm
12 Sep 2023

Latest updates on ACP's priorities, initiatives

ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
https://acpinternist.org/archives/2023/11/latest-updates-on-acps-priorities-initiatives.htm
1 Nov 2023

Routine opioid use disorder screening fails to significantly increase new diagnosis rates

This may be due to the sensitivity of the screening instrument, compounded by the stigma of opioid use disorder; addressing the latter may increase the instrument's sensitivity, the authors suggest.
https://acpinternist.org/weekly/archives/2023/10/17/2.htm
17 Oct 2023

Big barrier to buprenorphine removed

The U.S. government no longer requires an X waiver to treat patients with buprenorphine for opioid use disorder.
https://acpinternist.org/archives/2023/03/big-barrier-to-buprenorphine-removed.htm
1 Mar 2023

Drug screens early during treatment for OUD predict risk of return to opioid use

Patients whose urine drug screens in the three weeks after beginning treatment for opioid use disorder (OUD) were negative for opioids had a 13% risk of returning to opioid use compared with 85% for those with three weeks of opioid-positive or missing results.
https://acpinternist.org/weekly/archives/2023/10/10/2.htm
10 Oct 2023

Learn the latest on excessive alcohol use, opioid use disorder

This month's issue addresses alcohol use and misuse, prescribing buprenorphine, and improving health care's response to future pandemics.
https://acpinternist.org/archives/2023/03/learn-the-latest-on-excessive-alcohol-use-opioid-use-disorder.htm
1 Mar 2023

One-third of primary care physicians do not support medications for opioid use disorder

Fewer than a quarter of surveyed primary care physicians expressed interest in treating patients with opioid use disorder, and only 11.8% were interested in obtaining a waiver to prescribe buprenorphine.
https://acpinternist.org/weekly/archives/2020/04/21/2.htm
21 Apr 2020

Leadership, Leadership Day, and ‘purple’ as a guide

ACP's Chief Advocacy Officer issues a challenge to members of the College to be more “purple” in their outlook in order to achieve goals as a team, even when they disagree.
https://acpinternist.org/archives/2023/07/leadership-leadership-day-and-purple-as-a-guide.htm
1 Jul 2023

Daily medication appears more cost-effective than monthly injections for opioid use disorder

Over 24 weeks, extended-release naltrexone cost an average of $5,317 more than buprenorphine-naloxone, primarily because the former was more expensive and required a longer detoxification period.
https://acpinternist.org/weekly/archives/2018/12/18/1.htm
18 Dec 2018

Q&A: DEA requires addiction training for all prescribers

The Drug Enforcement Administration is requiring eight hours of training related to substance use disorder treatment, sending clinicians scurrying to their continuing education providers for help.
https://acpinternist.org/archives/2023/05/dea-requires-addiction-training-for-all-prescribers.htm
1 May 2023

Result Page: Prev   1   2   3   4   5   6   Next